CA
NZ
UK
AU
IND
US
Jersey Mike's Subs Inc. filed an 8-K on September 22, 2026, disclosing that Blackstone affiliates pledged a combined 172,621,820 shares of company stock and 44,990,370 common units as collateral for margin loan agreements totaling approximately $1.09 billion, with Morgan Stanley Senior Funding, Inc. serving …
Filana Therapeutics, Inc. filed a Form 8-K on September 22, 2026, disclosing that the U.S. Food and Drug Administration lifted the full clinical hold on its investigational new drug application for simufilam in tuberous sclerosis complex-related epilepsy.
PDS Biotechnology Corporation filed a Form 8-K on September 22, 2026, disclosing a press release announcing the publication of Phase 2 trial results for its HPV16-targeted immunotherapy PDS0101 in combination with pembrolizumab in the September 17, 2026, issue of JAMA Oncology.
SCYNEXIS, Inc. filed a current report on Form 8-K on September 22, 2026, disclosing the appointment of Steven K. Burke, M.D., as a new member of its Board of Directors, effective September 18, 2026.
Solaris Energy Infrastructure, Inc. filed an 8-K on September 22, 2026, disclosing that its subsidiary intends to offer $1.0 billion aggregate principal amount of Senior Notes due 2032 in a private placement under Rule 144A and Regulation S.
General Electric Company, operating as GE Aerospace, filed a current report on September 22, 2026, disclosing two board-level governance changes effective September 21, 2026: the appointment of Judson Althoff to the Audit Committee and the appointment of Wesley Bush as independent Lead Director.
LandBridge Company LLC filed a Form 8-K on September 22, 2026, disclosing that its subsidiary DBR Land Holdings LLC intends to offer an additional $100,000,000 in aggregate principal amount of 6.250% Senior Notes due 2030 in a private placement, subject to market conditions.
Open Text Corporation filed an 8-K with the U.S. Securities and Exchange Commission on September 22, 2026, disclosing a conditional notice of redemption for $1.0 billion of its 6.900% Senior Secured Notes due 2027, a potential new senior secured notes offering, and plans to …
Compass Therapeutics, Inc. filed a Form 8-K with the SEC on September 22, 2026, disclosing that it received regulatory feedback from the FDA relating to tovecimig in patients with biliary tract cancer, with the full details contained in an attached press release.
Millrose Properties, Inc. filed an 8-K with the SEC on September 22, 2026, disclosing plans to offer up to $1,000,000,000 in aggregate principal amount of senior notes in two separate tranches, subject to market conditions.
Please wait processing your request...